Literature DB >> 10766988

Splicing mutation in dysferlin produces limb-girdle muscular dystrophy with inflammation.

E M McNally1, C T Ly, H Rosenmann, S Mitrani Rosenbaum, W Jiang, L V Anderson, D Soffer, Z Argov.   

Abstract

Mutations in dysferlin were recently described in patients with Miyoshi myopathy, a disorder that preferentially affects the distal musculature, and in patients with Limb-Girdle Muscular Dystrophy 2B, a disorder that affects the proximal musculature. Despite the phenotypic differences, the types of mutations associated with Miyoshi myopathy and Limb-Girdle Muscular Dystrophy 2B do not differ significantly. Thus, the etiology of the phenotypic variability associated with dysferlin mutations remains unknown. Using genetic linkage and mutation analysis, we identified a large inbred pedigree of Yemenite Jewish descent with limb-girdle muscular dystrophy. The phenotype in these patients included slowly progressive, proximal, and distal muscular weakness in the lower limbs with markedly elevated serum creatine kinase (CK) levels. These patients had normal development and muscle strength and function in early life. Muscle biopsies from 4 affected patients showed a typical dystrophic pattern but interestingly, in 2, an inflammatory process was seen. The inflammatory infiltrates included primarily CD3 positive lymphocytes. Associated with this phenotype, we identified a previously undescribed frameshift mutation at nucleotide 5711 of dysferlin. This mutation produced an absence of normal dysferlin mRNA synthesis by affecting an acceptor site and cryptic splicing. Thus, splice site mutations that disrupt dysferlin may produce a phenotype associated with inflammation. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10766988     DOI: 10.1002/(sici)1096-8628(20000410)91:4<305::aid-ajmg12>3.0.co;2-s

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  28 in total

1.  Myopathy caused by anoctamin 5 mutations and necrotizing vasculitis.

Authors:  Isabelle Pénisson-Besnier; Jean-Paul Saint-André; Debbie Hicks; Anna Sarkozy; Anne Croué; Judith Hudson; Hanns Lochmüller; Frédéric Dubas
Journal:  J Neurol       Date:  2012-04-19       Impact factor: 4.849

2.  Reduced plasma membrane expression of dysferlin mutants is attributed to accelerated endocytosis via a syntaxin-4-associated pathway.

Authors:  Frances J Evesson; Rachel A Peat; Angela Lek; Fabienne Brilot; Harriet P Lo; Russell C Dale; Robert G Parton; Kathryn N North; Sandra T Cooper
Journal:  J Biol Chem       Date:  2010-07-01       Impact factor: 5.157

Review 3.  Regulatory interactions between muscle and the immune system during muscle regeneration.

Authors:  James G Tidball; S Armando Villalta
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2010-03-10       Impact factor: 3.619

4.  Coupling of excitation to Ca2+ release is modulated by dysferlin.

Authors:  Valeriy Lukyanenko; Joaquin M Muriel; Robert J Bloch
Journal:  J Physiol       Date:  2017-06-26       Impact factor: 5.182

5.  Clinical and genetic analysis of Korean patients with Miyoshi myopathy: identification of three novel mutations in the DYSF gene.

Authors:  Hyun-Jung Cho; Duck Hyun Sung; Eun-Jin Kim; Chul Ho Yoon; Chang-Seok Ki; Jong-Won Kim
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

Review 6.  [Limb girdle muscular dystrophies].

Authors:  J Finsterer
Journal:  Nervenarzt       Date:  2004-12       Impact factor: 1.214

7.  Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B.

Authors:  Kanneboyina Nagaraju; Rashmi Rawat; Edina Veszelovszky; Rachana Thapliyal; Akanchha Kesari; Susan Sparks; Nina Raben; Paul Plotz; Eric P Hoffman
Journal:  Am J Pathol       Date:  2008-02-14       Impact factor: 4.307

8.  Extensive mononuclear infiltration and myogenesis characterize recovery of dysferlin-null skeletal muscle from contraction-induced injuries.

Authors:  Joseph A Roche; Richard M Lovering; Renuka Roche; Lisa W Ru; Patrick W Reed; Robert J Bloch
Journal:  Am J Physiol Cell Physiol       Date:  2009-11-18       Impact factor: 4.249

9.  1α,25(OH)(2)-Vitamin D3 increases dysferlin expression in vitro and in a human clinical trial.

Authors:  Noemi De Luna; Jordi Díaz-Manera; Carmen Paradas; Cristina Iturriaga; Ricardo Rojas-García; Josefa Araque; Mireia Genebriera; Ignasi Gich; Isabel Illa; Eduard Gallardo
Journal:  Mol Ther       Date:  2012-08-21       Impact factor: 11.454

10.  Attenuated muscle regeneration is a key factor in dysferlin-deficient muscular dystrophy.

Authors:  Yen-Hui Chiu; Mark A Hornsey; Lars Klinge; Louise H Jørgensen; Steven H Laval; Richard Charlton; Rita Barresi; Volker Straub; Hanns Lochmüller; Kate Bushby
Journal:  Hum Mol Genet       Date:  2009-03-13       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.